MedTrace Logo

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

NCT04795869 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-10-10

No results posted yet for this study

Summary

This phase II clinical trial studies how well giving brentuximab vedotin together with pembrolizumab in treating patients with peripheral T-cell lymphoma (PTCL) that has come back (recurrent). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Pembrolizumab is an antibody-drug that stimulates body's natural antitumor immune responses. Giving brentuximab vedotin together with pembrolizumab may work better than brentuximab vedotin alone in treating patients with recurrent peripheral T-cell lymphoma.

Conditions

  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • Recurrent Enteropathy-Associated T-Cell Lymphoma
  • Recurrent Follicular T-Cell Lymphoma
  • Recurrent Hepatosplenic T-Cell Lymphoma
  • Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
  • Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma
  • Refractory Angioimmunoblastic T-Cell Lymphoma
  • Refractory Enteropathy-Associated T-Cell Lymphoma
  • Refractory Follicular T-Cell Lymphoma
  • Refractory Hepatosplenic T-Cell Lymphoma
  • Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
  • Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma

Interventions

DRUG

Brentuximab Vedotin

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

Sponsors & Collaborators

Principal Investigators

  • Jonathan Moreira, MD · Northwestern University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2026-03-15
Completion
2029-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04795869 on ClinicalTrials.gov